Cargando…
Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity
BACKGROUND/AIMS: Prematurely born infants undergo costly, stressful eye examinations to uncover the small fraction with retinopathy of prematurity (ROP) that needs treatment to prevent blindness. The aim was to develop a prediction tool (DIGIROP-Screen) with 100% sensitivity and high specificity to...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627649/ https://www.ncbi.nlm.nih.gov/pubmed/33980506 http://dx.doi.org/10.1136/bjophthalmol-2020-318719 |
_version_ | 1784606876111994880 |
---|---|
author | Pivodic, Aldina Johansson, Helena Smith, Lois E H Hård, Anna-Lena Löfqvist, Chatarina Yoder, Bradley A Hartnett, M Elizabeth Wu, Carolyn Bründer, Marie-Christine Lagrèze, Wolf A Stahl, Andreas Al-Hawasi, Abbas Larsson, Eva Lundgren, Pia Gränse, Lotta Sunnqvist, Birgitta Tornqvist, Kristina Wallin, Agneta Holmström, Gerd Albertsson-Wikland, Kerstin Nilsson, Staffan Hellström, Ann |
author_facet | Pivodic, Aldina Johansson, Helena Smith, Lois E H Hård, Anna-Lena Löfqvist, Chatarina Yoder, Bradley A Hartnett, M Elizabeth Wu, Carolyn Bründer, Marie-Christine Lagrèze, Wolf A Stahl, Andreas Al-Hawasi, Abbas Larsson, Eva Lundgren, Pia Gränse, Lotta Sunnqvist, Birgitta Tornqvist, Kristina Wallin, Agneta Holmström, Gerd Albertsson-Wikland, Kerstin Nilsson, Staffan Hellström, Ann |
author_sort | Pivodic, Aldina |
collection | PubMed |
description | BACKGROUND/AIMS: Prematurely born infants undergo costly, stressful eye examinations to uncover the small fraction with retinopathy of prematurity (ROP) that needs treatment to prevent blindness. The aim was to develop a prediction tool (DIGIROP-Screen) with 100% sensitivity and high specificity to safely reduce screening of those infants not needing treatment. DIGIROP-Screen was compared with four other ROP models based on longitudinal weights. METHODS: Data, including infants born at 24–30 weeks of gestational age (GA), for DIGIROP-Screen development (DevGroup, N=6991) originate from the Swedish National Registry for ROP. Three international cohorts comprised the external validation groups (ValGroups, N=1241). Multivariable logistic regressions, over postnatal ages (PNAs) 6–14 weeks, were validated. Predictors were birth characteristics, status and age at first diagnosed ROP and essential interactions. RESULTS: ROP treatment was required in 287 (4.1%)/6991 infants in DevGroup and 49 (3.9%)/1241 in ValGroups. To allow 100% sensitivity in DevGroup, specificity at birth was 53.1% and cumulatively 60.5% at PNA 8 weeks. Applying the same cut-offs in ValGroups, specificities were similar (46.3% and 53.5%). One infant with severe malformations in ValGroups was incorrectly classified as not needing screening. For all other infants, at PNA 6–14 weeks, sensitivity was 100%. In other published models, sensitivity ranged from 88.5% to 100% and specificity ranged from 9.6% to 45.2%. CONCLUSIONS: DIGIROP-Screen, a clinical decision support tool using readily available birth and ROP screening data for infants born GA 24–30 weeks, in the European and North American populations tested can safely identify infants not needing ROP screening. DIGIROP-Screen had equal or higher sensitivity and specificity compared with other models. DIGIROP-Screen should be tested in any new cohort for validation and if not validated it can be modified using the same statistical approaches applied to a specific clinical setting. |
format | Online Article Text |
id | pubmed-8627649 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-86276492022-10-28 Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity Pivodic, Aldina Johansson, Helena Smith, Lois E H Hård, Anna-Lena Löfqvist, Chatarina Yoder, Bradley A Hartnett, M Elizabeth Wu, Carolyn Bründer, Marie-Christine Lagrèze, Wolf A Stahl, Andreas Al-Hawasi, Abbas Larsson, Eva Lundgren, Pia Gränse, Lotta Sunnqvist, Birgitta Tornqvist, Kristina Wallin, Agneta Holmström, Gerd Albertsson-Wikland, Kerstin Nilsson, Staffan Hellström, Ann Br J Ophthalmol Clinical Science BACKGROUND/AIMS: Prematurely born infants undergo costly, stressful eye examinations to uncover the small fraction with retinopathy of prematurity (ROP) that needs treatment to prevent blindness. The aim was to develop a prediction tool (DIGIROP-Screen) with 100% sensitivity and high specificity to safely reduce screening of those infants not needing treatment. DIGIROP-Screen was compared with four other ROP models based on longitudinal weights. METHODS: Data, including infants born at 24–30 weeks of gestational age (GA), for DIGIROP-Screen development (DevGroup, N=6991) originate from the Swedish National Registry for ROP. Three international cohorts comprised the external validation groups (ValGroups, N=1241). Multivariable logistic regressions, over postnatal ages (PNAs) 6–14 weeks, were validated. Predictors were birth characteristics, status and age at first diagnosed ROP and essential interactions. RESULTS: ROP treatment was required in 287 (4.1%)/6991 infants in DevGroup and 49 (3.9%)/1241 in ValGroups. To allow 100% sensitivity in DevGroup, specificity at birth was 53.1% and cumulatively 60.5% at PNA 8 weeks. Applying the same cut-offs in ValGroups, specificities were similar (46.3% and 53.5%). One infant with severe malformations in ValGroups was incorrectly classified as not needing screening. For all other infants, at PNA 6–14 weeks, sensitivity was 100%. In other published models, sensitivity ranged from 88.5% to 100% and specificity ranged from 9.6% to 45.2%. CONCLUSIONS: DIGIROP-Screen, a clinical decision support tool using readily available birth and ROP screening data for infants born GA 24–30 weeks, in the European and North American populations tested can safely identify infants not needing ROP screening. DIGIROP-Screen had equal or higher sensitivity and specificity compared with other models. DIGIROP-Screen should be tested in any new cohort for validation and if not validated it can be modified using the same statistical approaches applied to a specific clinical setting. BMJ Publishing Group 2022-11 2021-05-12 /pmc/articles/PMC8627649/ /pubmed/33980506 http://dx.doi.org/10.1136/bjophthalmol-2020-318719 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Clinical Science Pivodic, Aldina Johansson, Helena Smith, Lois E H Hård, Anna-Lena Löfqvist, Chatarina Yoder, Bradley A Hartnett, M Elizabeth Wu, Carolyn Bründer, Marie-Christine Lagrèze, Wolf A Stahl, Andreas Al-Hawasi, Abbas Larsson, Eva Lundgren, Pia Gränse, Lotta Sunnqvist, Birgitta Tornqvist, Kristina Wallin, Agneta Holmström, Gerd Albertsson-Wikland, Kerstin Nilsson, Staffan Hellström, Ann Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity |
title | Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity |
title_full | Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity |
title_fullStr | Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity |
title_full_unstemmed | Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity |
title_short | Development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity |
title_sort | development and validation of a new clinical decision support tool to optimize screening for retinopathy of prematurity |
topic | Clinical Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8627649/ https://www.ncbi.nlm.nih.gov/pubmed/33980506 http://dx.doi.org/10.1136/bjophthalmol-2020-318719 |
work_keys_str_mv | AT pivodicaldina developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT johanssonhelena developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT smithloiseh developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT hardannalena developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT lofqvistchatarina developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT yoderbradleya developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT hartnettmelizabeth developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT wucarolyn developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT brundermariechristine developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT lagrezewolfa developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT stahlandreas developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT alhawasiabbas developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT larssoneva developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT lundgrenpia developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT granselotta developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT sunnqvistbirgitta developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT tornqvistkristina developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT wallinagneta developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT holmstromgerd developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT albertssonwiklandkerstin developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT nilssonstaffan developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity AT hellstromann developmentandvalidationofanewclinicaldecisionsupporttooltooptimizescreeningforretinopathyofprematurity |